Helicobacter pylori surface and enzyme targets and gastric mucosal surface

Helicobacter pylori (H. pylori) utilizes a suite of surface proteins and enzymes to colonize the human gastric mucosal surface. A primary enzyme target is urease, which catalyzes the hydrolysis of urea into ammonia and carbon dioxide, neutralizing local gastric acid to facilitate bacterial survival (StatPearls, 2023). Surface targets include adhesins such as Blood group antigen-binding adhesin (BabA) and Sialic acid-binding adhesin (SabA), which mediate attachment to the gastric epithelium by interacting with host glycoconjugates (PubMed, PMID: 11748273). Therapeutic strategies typically involve triple or quadruple therapy regimens that combine antibiotics like clarithromycin and amoxicillin with proton pump inhibitors (PPIs) or potassium-competitive acid blockers (P-CABs) to eradicate the pathogen and promote mucosal healing (Mayo Clinic, 2023). Chronic infection of these targets is a major risk factor for the development of peptic ulcers, chronic gastritis, and gastric adenocarcinoma (World Health Organization, 2020). This entry is considered incorrect as a single target because it encompasses multiple distinct bacterial proteins and host tissue structures rather than a single molecular entity.

Other names

H. pylori infection targetsGastric niche componentsH. pylori virulence factorsGastric mucosal barrier

Inhibition of bacterial cell wall synthesis, inhibition of bacterial protein synthesis, inhibition of gastric H+/K+-ATPase (proton pump), disruption of bacterial cell membranes, and competitive inhibition of potassium-binding to the proton pump.